A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
Condition: Influenza Interventions: Biological: DCVC H1 HA mRNA vaccine; Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine; Other: Sodium Chloride, 0.9% Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Chloride | Infectious Diseases | Influenza | Influenza Vaccine | Research | Study | Vaccines